Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

5 Feb 2020

Abstract excerpt

BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations. METHODS: CAR-NK cells per kilogram of body weight) after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32023374
DOI: 10.1056/nejmoa1910607

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsPMID 32023374Read ↗

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read ↗

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndromeSemantic proximity Read ↗

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read ↗

CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignanciesSemantic proximity Read ↗

iPSC-derived CD19 CAR NK cells for relapsed or refractory lymphomaSemantic proximity Read ↗

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaSemantic proximity Read ↗

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.Semantic proximity Read ↗

Preferential disruption of HLA-A/B enhances allogeneic CAR-T cell expansion and antitumor capacity in B cell malignanciesSemantic proximity Read ↗

CAR NK Cells: The Future Is NowSemantic proximity Read ↗

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell MalignanciesSemantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

Engineered NKG2C <sup>+</sup> NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.